<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00535665</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-PanFlu-2001</org_study_id>
    <nct_id>NCT00535665</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine</brief_title>
  <official_title>The Clinical Trial of Pandemic Influenza Vaccine (Whole-Virion， Inactivated, Adjuvanted) on Healthy Adults by Randomized and Double-Blind Design: a Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, randomized and double-blind phase II clinical trial is to be conducted in&#xD;
      adults to evaluate the safety and immunogenicity of an inactivated pandemic influenza vaccine&#xD;
      (whole-virion, aluminium-adjuvanted).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The vaccine to be investigated is producted in embryonated hen's eggs using an H5N1 reference&#xD;
      strain NIBRG-14 which was prepared by NIBSC. The strain is a reassortant between&#xD;
      A/Vietnam/1194/2004 and A/PR/8/34 by reverse genetics.&#xD;
&#xD;
      Total 400 volunteers aged from 18 to 60 years old are to be enrolled with 100 subjects in&#xD;
      each group. The eligible volunteers will receive two doses vaccine of 5μg，10μg or 15μg&#xD;
      haemagglutinin antigen. The schedule is day 0,14 or day 0,28. The subjects will donate their&#xD;
      blood samples for the detection of HI antibody and microneutralization antibody. Local and&#xD;
      systematic adverse reactions will be recorded during the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HI antibody and Neutralization antibody</measure>
    <time_frame>0,28,42,56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse reactions</measure>
    <time_frame>0,28,42,56</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">402</enrollment>
  <condition>Pandemic Influenza</condition>
  <condition>Prevention</condition>
  <arm_group>
    <arm_group_label>1: 10 ug, 14 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2: 5 ug, 28 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3: 10 ug, 28 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4: 15 ug, 28days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pandemic influenza vaccine (H5N1 strain NIBRG-14)</intervention_name>
    <description>two-dose regimen with 14 days apart: 5 microgram per dose</description>
    <arm_group_label>1: 10 ug, 14 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pandemic influenza vaccine (H5N1 strain NIBRG-14)</intervention_name>
    <description>two-dose regimen with 28 days apart: 5 microgram per dose</description>
    <arm_group_label>2: 5 ug, 28 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pandemic influenza vaccine (H5N1 strain NIBRG-14)</intervention_name>
    <description>two-dose regimen with 28 days apart: 10 microgram per dose</description>
    <arm_group_label>3: 10 ug, 28 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pandemic influenza vaccine (H5N1 strain NIBRG-14)</intervention_name>
    <description>two-dose regimen with 28 days apart: 15 microgram per dose</description>
    <arm_group_label>4: 15 ug, 28days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults aged 18-60 years old&#xD;
&#xD;
          -  Be able to show legal identity card for the sake of recruitment&#xD;
&#xD;
          -  Be able to understand and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Woman： Who breast-feeding or planning to become pregnant during the 56 days of study&#xD;
             participation&#xD;
&#xD;
          -  Any history of allergic reactions was allergic to any component of the vaccine, such&#xD;
             as eggs or ovalbumin;&#xD;
&#xD;
          -  Any history of severe adverse reactions to vaccines, such as anaphylaxis, hives,&#xD;
             respiratory difficulty, angioedema, or abdominal pain&#xD;
&#xD;
          -  Autoimmune disease or immunodeficiency&#xD;
&#xD;
          -  Asthma that is unstable or required emergent care, hospitalization or intubation&#xD;
             during the past two years or that required the use of oral or intravenous&#xD;
             corticosteroids&#xD;
&#xD;
          -  Diabetes mellitus (type I or II), with the exception of gestational diabetes&#xD;
&#xD;
          -  History of thyroidectomy or thyroid disease that required medication within the past&#xD;
             12 months&#xD;
&#xD;
          -  Serious angioedema episodes within the previous 3 years or requiring medication in the&#xD;
             previous two years&#xD;
&#xD;
          -  Hypertension that was not well controlled by medication or is more than 145/95 mmHg at&#xD;
             enrollment&#xD;
&#xD;
          -  Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or&#xD;
             platelet disorder requiring special precautions) or significant bruising or bleeding&#xD;
             difficulties with IM injections or blood draws&#xD;
&#xD;
          -  Active malignancy or treated malignancy for which there is not reasonable assurance of&#xD;
             sustained cure or malignancy that is likely to recur during the period of study&#xD;
&#xD;
          -  Seizure disorder other than:&#xD;
&#xD;
               1. Febrile seizures under the age of two years old,&#xD;
&#xD;
               2. Seizures secondary to alcohol withdrawal more than 3 years ago, or&#xD;
&#xD;
               3. A singular seizure not requiring treatment within the last 3 years&#xD;
&#xD;
          -  Asplenia, functional asplenia or any condition resulting in the absence or removal o&#xD;
             the spleen&#xD;
&#xD;
          -  Guillain-Barre Syndrome&#xD;
&#xD;
          -  Women subjects with positive urinary pregnancy test&#xD;
&#xD;
          -  Any history of immunosuppressive medications or cytotoxic medications or inhaled&#xD;
             corticosteroids within the past six months (with the exception of corticosteroid nasal&#xD;
             spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated&#xD;
             dermatitis)&#xD;
&#xD;
          -  History of any blood products administration within 3 months before the dosing&#xD;
&#xD;
          -  Administration of any other investigational research agents within 30 days before the&#xD;
             dosing&#xD;
&#xD;
          -  Administration of any live attenuated vaccine within 30 days before the dosing&#xD;
&#xD;
          -  Administration of subunit or inactivated vaccines, e.g. pneumococcal vaccine, or&#xD;
             allergy treatment with antigen injections, within 14 days before the dosing&#xD;
&#xD;
          -  Be receiving anti-TB prophylaxis or therapy currently&#xD;
&#xD;
          -  Axillary temperature &gt;37.0 centigrade at the time of dosing&#xD;
&#xD;
          -  Psychiatric condition that precludes compliance with the protocol; past or present&#xD;
             psychoses; past or present bipolar disorder requiring therapy that has not been well&#xD;
             controlled on medication for the past two years; disorder requiring lithium; or&#xD;
             suicidal ideation occurring within five years prior to enrollment&#xD;
&#xD;
          -  Any medical, psychiatric, social condition, occupational reason or other&#xD;
             responsibility that, in the judgment of the investigator, is a contraindication to&#xD;
             protocol participation or impairs a volunteer's ability to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiang Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Centers for Diseases Control and Prevention</affiliation>
  </overall_official>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>September 24, 2007</study_first_submitted>
  <study_first_submitted_qc>September 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2007</study_first_posted>
  <last_update_submitted>November 8, 2007</last_update_submitted>
  <last_update_submitted_qc>November 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

